Literature DB >> 20471444

A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.

Michael Maes1, Piotr Galecki, Yong Seun Chang, Michael Berk.   

Abstract

This paper reviews the body of evidence that major depression is accompanied by a decreased antioxidant status and by induction of oxidative and nitrosative (IO&NS) pathways. Major depression is characterized by significantly lower plasma concentrations of a number of key antioxidants, such as vitamin E, zinc and coenzyme Q10, and a lowered total antioxidant status. Lowered antioxidant enzyme activity, e.g. glutathione peroxidase (GPX), is another hallmark of depression. The abovementioned lowered antioxidant capacity may impair protection against reactive oxygen species (ROS), causing damage to fatty acids, proteins and DNA by oxidative and nitrosative stress (O&NS). Increased ROS in depression is demonstrated by increased levels of plasma peroxides and xanthine oxidase. Damage caused by O&NS is shown by increased levels of malondialdehyde (MDA), a by-product of polyunsaturated fatty acid peroxidation and arachidonic acid; and increased 8-hydroxy-2-deoxyguanosine, indicating oxidative DNA damage. There is also evidence in major depression, that O&NS may have changed inactive autoepitopes to neoantigens, which have acquired immunogenicity and serve as triggers to bypass immunological tolerance, causing (auto)immune responses. Thus, depression is accompanied by increased levels of plasma IgG antibodies against oxidized LDL; and increased IgM-mediated immune responses against membrane fatty acids, like phosphatidyl inositol (Pi); oleic, palmitic, and myristic acid; and NO modified amino-acids, e.g. NO-tyrosine, NO-tryptophan and NO-arginine; and NO-albumin. There is a significant association between depression and polymorphisms in O&NS genes, like manganese superoxide dismutase, catalase, and myeloperoxidase. Animal models of depression very consistently show lowered antioxidant defences and activated O&NS pathways in the peripheral blood and the brain. In animal models of depression, antidepressants consistently increase lowered antioxidant levels and normalize the damage caused by O&NS processes. Antioxidants, such as N-acetyl-cysteine, compounds that mimic GPX activity, and zinc exhibit antidepressive effects. This paper reviews the pathways by which lowered antioxidants and O&NS may contribute to depression, and the (neuro)degenerative processes that accompany that illness. It is concluded that aberrations in O&NS pathways are--together with the inflammatory processes--key components of depression. All in all, the results suggest that depression belongs to the spectrum of (neuro)degenerative disorders.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471444     DOI: 10.1016/j.pnpbp.2010.05.004

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  282 in total

1.  Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.

Authors:  David Mischoulon; Jonathan E Alpert; Erland Arning; Teodoro Bottiglieri; Maurizio Fava; George I Papakostas
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

Review 2.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

Review 3.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 4.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 5.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

6.  Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice.

Authors:  Eva M Medina-Rodriguez; Derik Madorma; Gregory O'Connor; Brittany L Mason; Dongmei Han; Sapna K Deo; Mark Oppenheimer; Charles B Nemeroff; Madhukar H Trivedi; Sylvia Daunert; Eléonore Beurel
Journal:  Am J Psychiatry       Date:  2020-07-31       Impact factor: 18.112

7.  Total antioxidant capacity of diet and serum, dietary antioxidant vitamins intake, and serum hs-CRP levels in relation to depression scales in university male students.

Authors:  Mohammad Prohan; Reza Amani; Sorur Nematpour; Nabi Jomehzadeh; Mohammad Hossein Haghighizadeh
Journal:  Redox Rep       Date:  2014-02-14       Impact factor: 4.412

8.  Behavioral responses in rats submitted to chronic administration of branched-chain amino acids.

Authors:  Giselli Scaini; Gabriela C Jeremias; Camila B Furlanetto; Diogo Dominguini; Clarissa M Comim; João Quevedo; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  JIMD Rep       Date:  2013-11-09

9.  In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life.

Authors:  Juliana Brum Moraes; Michael Maes; Chutima Roomruangwong; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; George Anderson; Marta Kubera; Andre F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

10.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.